Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study
Authors:
Open Access
- 29 August 2024
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (10) , 4033-4043
Abstract
Although there is an approved indication for venetoclax and hypomethylating agents (VenHMA) and its use in different AML settings will be expanded in the following years, the management of the adverse events (AEs) lacks of harmonized algorithms during treatment of these patients. We have studied the incidence of relevant AEs of 43 patients who achieved a response to VenHMA and its management. Median overall survival of our cohort was 19 months. No patients discontinued treatment due to AEs after C3D1, Regarding severe AEs, high rates of grade 4 neutropenia (97.6%) and grade 4 thrombocytopenia (65.1%) were observed. Severe infectious AEs rate was 16%. Due to severe myelotoxicity, most patients required a progressive dose reduction of both venetoclax and hypomethylating agents during follow-up, being 87.8% at C6D1. Transfusional dependence rate was 91% and G-CSF was prescribed to 86% of the patients. Finally, there was not a significant difference in hemoglobin, platelets and absolute neutrophil count after achieving complete response comparing paired samples during follow-up, although cytopenia rate was high during initial follow-up. We conclude that dose reduction of VenHMA after achieving a response in patients diagnosed with AML is required in most patients and essential to avoid prolonged cytopenia-related adverse events and a rapid and standardized method on how to perform it might decrease the AEs rate.Keywords
Funding Information
- Universitat de Barcelona
This publication has 46 references indexed in Scilit:
- Long‐term follow‐up of VIALE‐A: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemiaAmerican Journal of Hematology, 2024
- Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemiaAmerican Journal of Hematology, 2022
- Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantationAnnals of Hematology, 2021
- Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trialThe Lancet Haematology, 2021
- Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b studyAmerican Journal of Hematology, 2020
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialThe Lancet Haematology, 2020
- Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patientsAmerican Journal of Hematology, 2020
- Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experienceLeukemia Research, 2020
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyThe Lancet Oncology, 2018
- Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose AdjustmentsClinical Therapeutics, 2017